AllSci News
Quince Therapeutics calls halt to lead program after Phase III failure
San Francisco-based Quince Therapeutics Inc., revealed that its pivotal Phase III NEAT clinical trial evaluating dexamethasone sodium phosphate encapsulated in autologous erythrocytes…
Calico Life Sciences' ABBV-CLS-628 secures US FDA Fast Track designation for ADPKD treatment
Calico Life Sciences LLC, a biotechnology company founded by Alphabet Inc., [announced](https://www.prnewswire.com/news-releases/calico-life-sciences-announces-us-fda-fast-track-designation-for-investigational-treatment-of-autosomal-dominant-polycystic-kidney-disease-302573172.html) on October 2, 2025 that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ABBV-CLS-6
Ichnos Glenmark Innovation's ISB 2001 secures US FDA Fast Track designation for multiple myeloma
Ichnos Glenmark Innovation (IGI) [announced](https://www.prnewswire.com/news-releases/ichnos-glenmark-innovation-igi-receives-us-fda-fast-track-designation-for-isb-2001-for-relapsedrefractory-multiple-myeloma-302445918.html) today that the US FDA has granted Fast Track designation for ISB 2001, an investigational trispecific antibody targeting relapsed or refractory multiple myeloma (RRMM) in adul
NS Pharma's NS-229 secures US FDA Fast Track designation for eosinophilic granulomatosis with polyangiitis
NS Pharma, Inc., a subsidiary of Nippon Shinyaku Co., Ltd., [announced](https://www.prnewswire.com/news-releases/fda-grants-fast-track-designation-to-ns-229-for-the-treatment-of-eosinophilic-granulomatosis-with-polyangiitis-302550236.html) on Sept. 9, 2025 that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to NS-229, an investigational selective Janus kinase 1 (JAK
Evorpacept Plus Zanidatamab Shows Promise in Phase 2 HER2+ Metastatic Breast Cancer Trial
ALX Oncology has unveiled promising positive clinical trials data for its investigational CD47 inhibitor evorpacept, demonstrating potential breakthrough therapeutic approaches in advanced HER2-positive metastatic breast cancer. The Phase 1b/2 clinical trial exploring evorpacept's combination with zanidatamab revealed intriguing insights into targeted cancer treatment strategies, highlighting the
PranaX Secures $17 Million Series A Funding to Advance Exosome Regenerative Medicine Technology
Houston-based regenerative biologics startup PranaX Corporation has secured $17 million in an oversubscribed Series A funding round, signaling growing investor interest in cutting-edge exosome wellness technologies. The startup funding round was led by a consortium of family offices, trusts, and individual investors with deep expertise across biotechnology, regenerative medicine, and healthcare in
Amgen returns OX40 mAb rocatinlimab to Kyowa Kirin
Kyowa Kirin Co., Ltd announced it will regain global control of the development and commercialization program for rocatinlimab, an investigational anti-OX40 monoclonal…
Formation Bio adds Chia Tai’s miR-124 molecule for autoimmune diseases in USD 500m deal
Formation Bio, a US-based AI-native biopharmaceutical company, signed up with China’s Jiangsu Chia Tai Feng Hai Pharmaceutical Co., Ltd (CTFH) for a…
HDM2006: First-in-Human Phase 1 Trial Explores HPK1 Inhibition in Advanced Solid Tumors
Researchers at Fudan University Shanghai Cancer Center have initiated a first-in-human clinical trial investigating HDM2006, an experimental drug targeting the Hematopoietic Progenitor Kinase 1 (HPK1) pathway in patients with advanced solid tumors. The [Phase 1 study](https://clinicaltrials.gov/study/NCT07377591) represents a critical early step in evaluating the safety, tolerability, and potentia
Tenpoint bags USD 235m in financial support for Yuvezzi launch
Tenpoint Therapeutics, Ltd., a London- and Seattle-based biotechnology company focused on developing therapies to rejuvenate vision in the aging eye, said it…
AstraZeneca strikes USD 18.5b license deal for CSPC obesity pipeline
China’s CSPC Pharmaceutical Group and UK-based AstraZeneca formed a strategic collaboration and license agreement focused on CSPC’s innovative long-acting peptide medicines, anchored…
Moderna and Recordati Seal $160M mRNA Rare Disease Therapy Development Deal
Moderna and Recordati have announced a strategic collaboration to develop and commercialize mRNA-3927, an investigational therapy for propionic acidemia (PA), marking a significant business partnership news event in the rare disease therapeutics space. Under the agreement, Moderna will lead clinical development while Recordati will manage global commercialization, combining the biotech leader's mR
Summit seeking 1st US approval for Akeso’s PD-1/VEGF ivonescimab
Summit Therapeutics Inc., has filed a Biologics License Application (BLA) with the US FDA for ivonescimab, seeking approval for the bispecific antibody…
Breakthru Medicine gets USD 60m in Series A for molecular glues
Breakthru Medicine, a biotechnology company based in Phoenix, Arizona, closed a Series A financing round totaling USD 60 million to support its…
OMEICOS' OMT-28 Shows Promise in Phase 2a Trial for Primary Mitochondrial Diseases
OMEICOS Advances Mitochondrial Disease Therapy with Promising Phase 2a Results OMEICOS Therapeutics ...
The AllSci Brief
Free, systematic R&D and deal news. Daily.